Novo Holdings has announced that it wil co-lead with Vivo Capital the over-subscribed US$200-million Series A and Crossover round in Esco Lifesciences Group (“Esco”), a leading provider of life sciences tools and services. The financing will enable Esco to strengthen its position through organic and external growth and transformation, as well as invest in China, thus addressing some of the most dynamic market segments and geographies. Other investors include two Asian sovereign wealth funds and the Singapore-based global investor, EDBI.
Esco is a world-leading manufacturer of laboratory and biopharma equipment and IVF medical devices that offers mission-critical equipment and advanced solutions to laboratories, clinics, and bio-pharma production sites in more than 100 countries, thus contributing to the future of life science research and manufacturing.
Kasim Kutay, Chief Executive Officer of Novo Holdings, said, “As a long term, global life sciences investor, Novo Holdings is delighted to be partnering with the like-minded team at Esco. The opportunities for growth and expansion at Esco are significant and we look forward to bringing to bear our patient capital and life science expertise to the realisation of the Company’s strategy.”
Amit Kakar, Senior Partner, Head of Novo Holdings Asia, added, “Novo Holdings established its Asia presence with the opening of its Singapore office in January of this year and our investment in Esco is a very important milestone in the development of our regional ambitions. This investment builds on Novo’s strategy to identify and invest in life science and healthcare companies which are true leaders in their field, and Esco, with its deep-rooted history, track record and expertise has a stellar reputation for innovation in the global laboratory and cleanroom industry.”
XQ Lin, Chairman and Chief Executive Officer of Esco Lifesciences, commented, “We are pleased to welcome Novo Holdings, one of the most experienced life sciences investors globally, to Esco. This financing is a significant milestone for the Company as we embark on our Esco 3.0 transformation.”
SOURCE: Novo Holdings
